Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model
The cost-effectiveness of switching from nusinersen to risdiplam is evident across all SMA types. Further research on the long-term impact of switching treatments in SMA is essential to address uncertainties and optimize cost-effective therapeutic strategies.
Authors
- Slobodan Јаnkovic (ORCID: https://orcid.org/0000-0002-1519-8828)
- Dinko Vitezić (ORCID: https://orcid.org/0000-0002-6295-6580)
- Andrej Belančić (ORCID: https://orcid.org/0000-0001-7848-6600)
- Ivana Stević (ORCID: https://orcid.org/0000-0001-8880-7092)
- Elvira Meni Maria Gkrinia (ORCID: https://orcid.org/0009-0002-1255-8653)
Institutions
- University of Kragujevac (RS)
- University of Rijeka (HR)
- University of Belgrade (RS)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-12-14
- DOI
- https://doi.org/10.1002/bcp.70379
- Primary Topic
- Neurogenetic and Muscular Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00